What Liba Laboratuarları does

Liba Laboratuarları A.Ş. is a privately-held Turkish pharmaceutical company headquartered in Kavacık, Beykoz, Istanbul, that has operated continuously since its founding in 1945. The company concentrates on three therapeutic areas — central nervous system (CNS), gastroenterology, and antidotes — and serves healthcare institutions, pharmacies, and physicians through regulated pharmaceutical distribution channels within Turkey. Workforce size is reported at 51–100 employees, placing it in the small-to-mid-sized specialty pharma segment.

The product portfolio combines proprietary branded medicines with in-licensed international brands. Proprietary products include Libalaks (a lactulose-based gastroenterology preparation), Laksafenol, Libenta, and Epizonya (CNS). In-licensed products include Convulex (sodium valproate, for epilepsy) from Austrian partner G.L. Pharma and Suboxone (buprenorphine/naloxone, for opioid dependence) from UK-listed Indivior. These licensing arrangements are central to the company's go-to-market and provide differentiated specialty assets, particularly in CNS and addiction medicine, that the company itself does not develop.

The business model is a traditional pharmaceutical sales-and-distribution model, generating revenue through prescription-product sales into the Turkish healthcare system. The company has been family-controlled since inception, with Murat Sait Barlas assuming leadership in 1975. The legal entity was reorganized as a joint-stock company (Anonim Şirketi) in 1966 and relocated to its current Kavacık headquarters in 1994. No equity funding events, M&A activity, geographic expansion beyond Turkey, or product launches within the recent past are disclosed in the available material.

Name

Liba Laboratuarları

Legal name

Liba Laboratuarları AŞ

Website

https://liba.com.tr

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

51–100 employees

Short description

Liba Laboratuarları A.Ş. is a Turkish pharmaceutical company founded in 1945 that distributes proprietary and in-licensed prescription medicines across CNS, gastroenterology, and antidotes to healthcare institutions and pharmacies in Turkey.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industry

Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Central nervous system drugs
• Gastroenterology medicines
• Chelation therapy antidotes

Headquarters

HQ city

Anadoluhisari

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Liba Laboratuarları generates revenue through the manufacture and sale of prescription and over-the-counter pharmaceutical products. The company produces medications across three therapeutic areas: Central Nervous System, Gastroenterology, and Antidotes. Revenue is derived from product sales to healthcare institutions, pharmacies, and medical professionals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Liba Laboratuarları A.Ş. is a Turkish pharmaceutical manufacturer founded in 1945 that develops, produces, and distributes prescription medications across three therapeutic areas: Central Nervous System (epilepsy treatments such as Convulex and Epizonya, opioid addiction therapy Suboxone), Gastroenterology (constipation treatments Libalaks and Laksafenol), and Antidotes (lead poisoning chelation therapy Libenta). The company serves healthcare professionals and institutions primarily through Turkey's regulated pharmaceutical distribution network, with selected products licensed from partners including G.L. Pharma and Indivior.

Product overview

Liba Laboratuarları A.Ş. is a Turkish pharmaceutical company established in 1945, specializing in the development and distribution of prescription medications. The company offers a portfolio of pharmaceutical products organized across three main therapeutic areas: Central Nervous System (Convulex, Epizonya, Suboxone), Gastroenterology (Laksafenol, Libalaks), and Antidote (Libenta products). Liba serves public health needs through partnerships with international pharmaceutical companies including G.L. Pharma, Indivior, and others, providing medications for conditions such as epilepsy, opioid addiction, constipation, and lead poisoning.

Differentiator

Problem solved

Functional benefit

Products and services

• Convulex 50 mg/ml Pediatric Syrup (Convulex 50 mg/ml Pediatrik Şurup) Pediatric syrup medication for the Central Nervous System therapeutic area, containing Sodium Valproate as the active ingredient for the treatment of epilepsy. Commercial form is a 100 ml bottle; licensed by G.L. Pharma and distributed by Liba in Turkey.
• Epizonya 100 mg Capsule (Epizonya 100 mg Kapsül) Capsule medication for the Central Nervous System therapeutic area, containing Zonisamide as the active ingredient for the treatment of epilepsy. Commercial form is 100 mg, 100 capsules.
• Suboxone 2 mg/0.5 mg Sublingual Tablet (Suboxone 2 mg/0.5 mg Dilaltı Tablet) Sublingual tablet medication for the Central Nervous System therapeutic area, containing 2 mg Buprenorphine and 0.5 mg Naloxone as active ingredients, used for the treatment of opioid addiction and withdrawal. Licensed by Indivior and distributed by Liba in Turkey.
• Suboxone 8 mg/2 mg Sublingual Tablet (Suboxone 8 mg/2 mg Dilaltı Tablet) Sublingual tablet medication for the Central Nervous System therapeutic area, containing 8 mg Buprenorphine and 2 mg Naloxone as active ingredients, used for the treatment of opioid addiction and withdrawal. Commercial form is 28 sublingual tablets; licensed by Indivior.
• Laksafenol 50 mg Tablet Tablet medication for the Gastroenterology therapeutic area, containing Phenolphthalein as the active ingredient for the treatment of constipation. Commercial form is 20 tablets.
• Libalaks 53.1% + 37% Rectal Gel Enema (Libalaks %53.1 + %37 Rektal Jel) Rectal gel (enema) medication for the Gastroenterology therapeutic area, containing Glycerin and Sorbitol as active ingredients for the treatment of constipation. Commercial form is a 10g tube.
• Libenta 400 mg/2 ml Solution for Injection (Libenta 400 mg/2 ml Enjeksiyonluk Çözelti) Injection solution for the Antidote therapeutic area used in chelation therapy for lead poisoning. Commercial form is 2 ml x 10 ampoules or 2 ml x 100 ampoules. Licensed by Liba Laboratuarları A.Ş.
• Libenta Ampoule (Libenta Ampül) Ampoule medication for the Antidote therapeutic area, containing Calcium Disodium Edetate as the active ingredient for chelation therapy in lead poisoning treatment. Commercial form is 2 ml x 10 Ampules or 2 ml x 100 Ampules; licensed by Liba Laboratuarları A.Ş.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered licensor.

• G.L. PharmalicensorTechnology or IntegrationG.L. Pharma is the licensor for Convulex 50 mg/ml Pediatric Syrup (sodium valproate), a product distributed by Liba in Turkey for the treatment of epilepsy.
• IndiviorlicensorTechnology or IntegrationIndivior is the licensor for Suboxone sublingual tablets (buprenorphine/naloxone), products distributed by Liba in Turkey for the treatment of opioid addiction and withdrawal.

Scale indicators3 records

Recent moves5 records

Expansion highlights1 record

Direct peers

• İstanbul İlaç Sanayi ve Ticaret A.Ş. Turkish pharmaceutical manufacturer of branded generics and specialty products distributed domestically to physicians and pharmacies via medical reps; similar scale and go-to-market to Liba.
• Sanovel İlaç Sanayi ve Ticaret A.Ş. Mid-sized Turkish pharmaceutical company with branded generics across multiple therapy areas distributed nationally via field force; comparable in scale, channel, and product breadth to Liba.
• Nobel İlaç Sanayii ve Ticaret A.Ş. Privately-held Turkish pharma with a broad specialty portfolio including CNS and gastroenterology, distributed through medical reps to HCPs and institutions — overlapping therapeutic focus and channel model with Liba.
• Atabay İlaç Fabrikası A.Ş. Long-established (founded 1939) Turkish pharmaceutical manufacturer with branded generics distributed to HCPs in Turkey; comparable heritage profile, scale, and B2B distribution to Liba.
• World Medicine İlaç Sanayi ve Ticaret A.Ş. Turkish specialty pharmaceutical company with a strong licensing-in model from international partners, competing in therapeutic areas such as CNS and GI — very analogous to Liba's licensing-driven portfolio strategy.
• Ali Raif İlaç Sanayi A.Ş. Mid-sized Turkish specialty pharmaceutical manufacturer with a multi-therapy portfolio (including CNS, GI, cardiology) sold through medical representatives — directly comparable to Liba's B2B specialty pharma model in the same domestic market.

Broad incumbents

• Abdi İbrahim İlaç Sanayi ve Ticaret A.Ş. Largest Turkish pharmaceutical company by revenue with a broad multi-therapy portfolio; competes with Liba in shared specialties (CNS, GI) as a much larger incumbent with greater R&D and licensing resources.
• Deva Holding A.Ş. One of Turkey's largest domestic pharma manufacturers with branded generics across multiple specialties; competes head-on with Liba in CNS and GI as a substantially larger established player.
• Eczacıbaşı İlaç Ticaret A.Ş. Diversified Turkish pharma arm of the Eczacıbaşı Group offering branded and specialty products across multiple therapy areas; a broader incumbent that overlaps with Liba's CNS and gastroenterology positions.

Others

• Selçuk Ecza Deposu Ticaret ve Sanayi A.Ş. Turkey's largest pharmaceutical wholesale distributor, the channel through which Liba's products reach retail pharmacies and institutions — comparable as an ecosystem participant in the same domestic pharma supply chain, though operating at a different functional layer.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/libalaboratuarlari

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liba Laboratuarları